Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07TGN
|
||||
| Former ID |
DAP000464
|
||||
| Drug Name |
Deslanoside
|
||||
| Synonyms |
Ceglunat; Desace; Deslanosido; Deslanosidum; Glucodigoxin; Lekozid; Sediranido; Deacetyllanatoside C; DesacetylLanatoside; Desacetyldigilanide C; Desacetyllanatoside C; Deslanatoside C; Deslanosidum C; Lanatosid C; Cedilanid-D; Desacetyl-Lanatoside C; Deslanosido [INN-Spanish]; Deslanosidum [INN-Latin]; Cedilanid-d (TN); Deslanoside (JP15/USP/INN); Deslanoside [USAN:BAN:INN:JAN]; (3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 3-[(O-beta-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy-12beta,14-dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy=12beta.14=dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12beta,14-dihydroxy-5beta-card-20(22)-enolide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Antiarrhythmic Agents
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C47H74O19
|
||||
| InChI |
InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1
|
||||
| InChIKey |
OBATZBGFDSVCJD-LALPQLPRSA-N
|
||||
| CAS Number |
CAS 17598-65-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
C01AA07
|
||||
| SuperDrug CAS ID |
cas=017598651
|
||||
| Target and Pathway | |||||
| Target(s) | Sodium/potassium-transporting ATPase alpha-1 chain | Target Info | Binder | [536316] | |
| KEGG Pathway | cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | |||||
| Cardiac muscle contraction | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Insulin secretion | |||||
| Thyroid hormone synthesis | |||||
| Thyroid hormone signaling pathway | |||||
| Aldosterone-regulated sodium reabsorption | |||||
| Endocrine and other factor-regulated calcium reabsorption | |||||
| Proximal tubule bicarbonate reclamation | |||||
| Salivary secretion | |||||
| Gastric acid secretion | |||||
| Pancreatic secretion | |||||
| Carbohydrate digestion and absorption | |||||
| Protein digestion and absorption | |||||
| Bile secretion | |||||
| Mineral absorption | |||||
| Reactome | Ion transport by P-type ATPases | ||||
| WikiPathways | Iron uptake and transport | ||||
| References | |||||
| Ref 538415 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 009282. | ||||
| Ref 541888 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6806). | ||||
| Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.